No evidence for substrate accumulation in Parkinson brains with GBA mutations
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: To establish whether Parkinson's disease (PD) brains previously described to have decreased glucocerebrosidase activity exhibit accumulation of the lysosomal enzyme's substrate, glucosylceramide, or other changes in lipid composition. Methods: Lipidomic analyses and cholesterol measurements were performed on the putamen (n = 5‐7) and cerebellum (n = 7‐14) of controls, Parkinson's disease brains with heterozygote GBA1 mutations (PD+GBA), or sporadic PD. Results: Total glucosylceramide levels were unchanged in both PD+GBA and sporadic PD brains when compared with controls. No changes in glucosylsphingosine (deacetylated glucosylceramide), sphingomyelin, gangliosides (GM2, GM3), or total cholesterol were observed in either putamen or cerebellum. Conclusions: This study did not demonstrate glucocerebrosidase substrate accumulation in PD brains with heterozygote GBA1 mutations in areas of the brain with low α‐synuclein pathology. © 2015 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475 · cited 1×
“GCase activity also has been reported to be decreased in the anterior cingulate cortex of sporadic PD brains.(5) Defects in the autophagy–lysosomal pathway (ALP) are implicated in the accumulation/aggregation of a-synuclein and mitochondrial dysfunction observed in PD.”
Background
Cited by
Sphingolipids: membrane microdomains in brain development, function and neurological diseases
Olsen, A. S. B., & Færgeman, N. J. (2017) · Open Biology · doi:10.1098/rsob.170069 · Cited by 311
Glucocerebrosidase and its relevance to Parkinson disease
Do, J., McKinney, C., Sharma, P., & Sidransky, E. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0336-2 · Cited by 300
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
Self-citationLysosomal dysfunction in neurodegeneration: emerging concepts and methods
Udayar, V., Chen, Y., Sidransky, E., & Jagasia, R. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2021.12.004 · Cited by 240
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203
Self-citationGlycosphingolipids and Neuroinflammation in Parkinson’s Disease
Belarbi, K., Cuvelier, E., Bonte, M.-A., Desplanque, M., Gressier, B., Devos, D., & Chartier-Harlin, M.-C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00408-1 · Cited by 155
Kuo, S.-H., Tasset, I., Cheng, M. M., Diaz, A., Pan, M.-K., Lieberman, O. J., Hutten, S. J., Alcalay, R. N., Kim, S., Ximénez-Embún, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm6393 · Cited by 153
“…in lysosomes, the reduced delivery of the enzyme to this compartment was also supported by the observation, consistent with previous reports ( 12 ), that levels of GCase activity in brains of PD-GBA patients were ~50% of healthy control levels, while we found normal levels of the lysosomal…”
Self-citationCurrent disease modifying approaches to treat Parkinson’s disease
Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O., & Saarma, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2101-1 · Cited by 99
Blumenreich, S., Nehushtan, T., Barav, O. B., Saville, J. T., Dingjan, T., Hardy, J., Fuller, M., & Futerman, A. H. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00363-2 · Cited by 31
What lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
Trends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry
Dehelean, L., Sarbu, M., Petrut, A., & Zamfir, A. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_42 · Cited by 16
Metadata
- Authors
- Gegg, M. E., Sweet, L., Wang, B. H., Shihabuddin, L. S., Sardi, S. P., & Schapira, A. H. V.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-06-11
- Volume
- 30
- Issue
- 8
- Pages
- 1085-1089
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1558432922
- Cited by
- 136
- References
- 5
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.